Vascular endothelial growth factor in the circulation in cancer patients may not be a relevant biomarker

PLoS ONE

Volumn 6, Issue 5, 2011, Pages

  Niers, Tatjana M H ^a   Richel, Dick J ^a   Meijers, Joost C M ^a   Schlingemann, Reinier O ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CITRIC ACID; PROSTAGLANDIN E1; THEOPHYLLINE; VASCULOTROPIN; BETA THROMBOGLOBULIN; THROMBOCYTE FACTOR 4; TUMOR MARKER; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ARTICLE; CANCER PATIENT; CELL ISOLATION; CIRCULATION; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CARCINOMA; METASTASIS POTENTIAL; PROTEIN SECRETION; THROMBOCYTE; THROMBOCYTE ACTIVATION; TUMOR VASCULARIZATION; AGED; BLOOD; CASE CONTROL STUDY; METABOLISM; MIDDLE AGED; NEOPLASM; PATHOPHYSIOLOGY;

AGED; BETA-THROMBOGLOBULIN; BLOOD PLATELETS; CASE-CONTROL STUDIES; HUMANS; MIDDLE AGED; NEOPLASMS; PLATELET ACTIVATION; PLATELET FACTOR 4; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 79957553592     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0019873     Document Type: Article

References (36)

1. Folkman J, (1995) Seminars in Medicine of the Beth Israel Hospital,Boston. Clinical applications of research on angiogenesis. N.Engl.J.Med 333: 1757-1763.
2. Veikkola T, Alitalo K, (1999) VEGFs, receptors and angiogenesis. Semin.Cancer Biol 9: 211-220.
3. Shibuya M, Claesson-Welsh L, (2006) Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis. Exp.Cell Res 312: 549-560.
4. Mohle R, Green D, Moore MA, Nachman RL, Rafii S, (1997) Constitutive production and thrombin-induced release of vascular endothelial growth factor by human megakaryocytes and platelets. Proc.Natl.Acad.Sci.U.S.A 94: 663-668.
5. Banks RE, Forbes MA, Kinsey SE, Stanley A, Ingham E, et al. (1998) Release of the angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets: significance for VEGF measurements and cancer biology. Br.J.Cancer 77: 956-964.
6. Verheul HM, Hoekman K, Luykx-de Bakker S, Eekman CA, Folman CC, et al. (1997) Platelet: transporter of vascular endothelial growth factor. Clin.Cancer Res 3: 2187-2190.
7. Gunsilius E, Petzer A, Stockhammer G, Nussbaumer W, Schumacher P, et al. (2000) Thrombocytes are the major source for soluble vascular endothelial growth factor in peripheral blood. Oncology 58: 169-174.
8. Webb NJ, Myers CR, Watson CJ, Bottomley MJ, Brenchley PE, (1998) Activated human neutrophils express vascular endothelial growth factor (VEGF). Cytokine 10: 254-257.
9. Witmer AN, Vrensen GF, Van Noorden CJ, Schlingemann RO, (2003) Vascular endothelial growth factors and angiogenesis in eye disease. Prog.Retin.Eye Res 22: 1-29.
10. Witmer AN, Dai J, Weich HA, Vrensen GF, Schlingemann RO, (2002) Expression of vascular endothelial growth factor receptors 1, 2, and 3 in quiescent endothelia. J.Histochem.Cytochem 50 (6): 767-777.
11. Longo R, Gasparini G, (2007) Challenges for patient selection with VEGF inhibitors. Cancer Chemother.Pharmacol 60: 151-170.
12. Salgado R, Vermeulen PB, Benoy I, Weytjens R, Huget P, et al. (1999) Platelet number and interleukin-6 correlate with VEGF but not with bFGF serum levels of advanced cancer patients. Br.J.Cancer 80: 892-897.
13. Hyodo I, Doi T, Endo H, Hosokawa Y, Nishikawa Y, et al. (1998) Clinical significance of plasma vascular endothelial growth factor in gastrointestinal cancer. Eur.J.Cancer 34: 2041-2045.
14. Davies MM, Jonas SK, Kaur S, Allen-Mersh TG, (2000) Plasma vascular endothelial but not fibroblast growth factor levels correlate with colorectal liver mestastasis vascularity and volume. Br. J. Cancer 82: 1004-1008.
15. Yoshikawa T, Tsuburaya A, Kobayashi O, Sairenji M, et al. (2000) Plasma concentrations of VEGF and bFGF in patients with gastric carcinoma. Cancer Lett 153: 7-12.
16. Gnarra JR, Zhou S, Merrill MJ, Wagner JR, Krumm A, et al. (1996) Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene. Proc.Natl.Acad.Sci.U.S.A 93: 10589-10594.
17. Iliopoulos O, Levy AP, Jiang C, Kaelin WG Jr, Goldberg MA, (1996) Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proc.Natl.Acad.Sci.U.S.A 93: 10595-10599.
18. Mukhopadhyay D, Knebelmann B, Cohen HT, Ananth S, Sukhatme VP, (1997) The von Hippel-Lindau tumor suppressor gene product interacts with Sp1 to repress vascular endothelial growth factor promoter activity. Mol.Cell Biol 17: 5629-5639.
19. Kapitsinou PP, Haasse PP, (2008) The VHL tumor suppressor and HIF; insights from genetic studies in mice. Cell Death and differentiation 15: 650-659.
20. Nyhan MJ, O'Sullivan GC, McKenna SL, (2008) Role of the VHL (von Hippel-Lindau) gene in renal cancer: a multifunctional tumour suppressor. Biochemical Society transactions 36: 472-478.
21. Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, et al. (1999) Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J.Clin.Oncol 17: 2530-2540.
22. Kaplan KL, Owen J, (1981) Plasma levels of beta-thromboglobulin and platelet factor 4 as indices of platelet activation in vivo. Blood 57: 199-202.
23. Kaplan KL, Owen L, Harker LA, (1986) Plasma Levels of platelet secretory proteins. Crit Rev Oncol. Hematol 5 (3): 235-255.
24. Caine GJ, Lip GY, Blann AD, (2004) Platelet-derived VEGF, Flt-1, angiopoietin-1 and P-selectin in breast and prostate cancer: further evidence for a role of platelets in tumour angiogenesis. Ann. Med 36: 273-277.
25. Werther K, Christensen IJ, Nielsen HJ, (2002) Determination of vascular endothelial growth factor (VEGF) in circulating blood: significance of VEGF in various leucocytes and platelets. Scand. J. Clin. Lab Invest 62: 343-350.
26. Kusumanto YH, Dam WA, Hospers GA, Meijer C, Mulder NH, (2003) Platelets and granulocytes, in particular the neutrophils, form important compartments for circulating vascular endothelial growth factor. Angiogenesis 6: 283-287.
27. Salven P, Orpana A, Joensuu H, (1999) Leukocytes and platelets of patients with cancer contain high levels of vascular endothelial growth factor. Clin Cancer Res 5: 487-491.
28. Verheul HM, Pinedo HM, (1998) Tumor Growth: A Putative Role for Platelets? Oncologist 3 (2).
29. Verheul HM, Jorna AS, Hoekman K, Broxterman HJ, Gebbink MF, et al. (2000) Vascular endothelial growth factor-stimulated endothelial cells promote adhesion and activation of platelets. Blood 96: 4216-4221.
30. Verheul HM, Hoekman K, Lupu F, Broxterman HJ, van der Valk P, et al. (2000) Platelet and coagulation activation with vascular endothelial growth factor generation in soft tissue sarcomas. Clin.Cancer Res 6: 166-171.
31. Rini BI, Small EJ, (2005) Biology and clinical development of vascular endothelial growth factor targeted therapy in renal cell carcinoma. J Clin Oncol 23 (5): 1028-1043.
32. Presta LG, Chen H, O Çonnor SJ, (1997) Humanization of an antivascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders Cancer Res 57: 4593-4599.
33. Yang JC, Haworth L, Sherry RM, et al. (2003) A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med: 349: 427-434.
34. Grothey A, Ellis LM, (2008) Targeting angiogenesis driven by endothelial growth factors using antibody based therapy. Cancer Journal 14 (3): 170-7.
35. Klement GL, Yip TT, Cassiola F, Kikuchi L, Cervi D, et al. (2009) Platelets actively sequester angiogenesis regulators. Blood 113 (12): 2835-2842.
36. George ML, Eccles SA, Tutton MG, Abulafi AM, Swift RI, (2000) Correlation of plasma and serum vascular endothelial growth factor levels with platelet count in colorectal cancer: clinical evidence of platelet scavenging? Clin.Cancer Res 6: 3147-3152.